F. Mallone, A. V. Chicca, P. Sagnelli, M. Sacchetti, A. Lambiase
{"title":"NEW INSIGHTS ON THE DIAGNOSIS AND MANAGEMENT OF MALIGNANT TUMORS OF THE OCULAR SURFACE","authors":"F. Mallone, A. V. Chicca, P. Sagnelli, M. Sacchetti, A. Lambiase","doi":"10.48286/aro.2021.15","DOIUrl":"https://doi.org/10.48286/aro.2021.15","url":null,"abstract":"","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123165110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Zichi, F. De Vita, J. Paparo, F. Salerno, D. Marino, E. Sperti, G. Lacidogna, F. Vignani, R. Dionisio, C. Baratelli, C. Turco, D. Ballaminut, A. Bellezza, P. Chiotto, G. Ciriolo, R. Comite, F. Codegone, S. Florio, L. Fusco, L. Polimeno, D. Pozzi, E. Zilio, V. Ariu, S. Terziolo, M. Di Maio
1 Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy 2 Department of Oncology, School of Medicine, University of Turin, Turin, Italy *Present address: Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy C. Zichi1,2, F. De Vita1,2, J. Paparo1,2, F. Salerno1,2, D. Marino1, E. Sperti1, G. Lacidogna1, F. Vignani1, R. Dionisio1, C. Baratelli1,2*, C. G. C. Turco1,2, D. Ballaminut1, A. Bellezza1, P. Chiotto1, G. Ciriolo1, R. Comite1, F. Codegone1, S. Florio1, L. Fusco1, L. Polimeno1, D. Pozzi1, E. Zilio1, V. Ariu1, S. Terzolo1, M. Di Maio1,2 ADOPTION OF PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE FOR OLDER PATIENTS RECEIVING ACTIVE ANTI-CANCER TREATMENT: IMPACT ON HEALTH-RELATED QUALITY OF LIFE Annals of Research in Oncology Vol. 1(4), 285-294, 2021
{"title":"ADOPTION OF PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE FOR OLDER PATIENTS RECEIVING ACTIVE ANTI-CANCER TREATMENT: IMPACT ON HEALTH-RELATED QUALITY OF LIFE","authors":"C. Zichi, F. De Vita, J. Paparo, F. Salerno, D. Marino, E. Sperti, G. Lacidogna, F. Vignani, R. Dionisio, C. Baratelli, C. Turco, D. Ballaminut, A. Bellezza, P. Chiotto, G. Ciriolo, R. Comite, F. Codegone, S. Florio, L. Fusco, L. Polimeno, D. Pozzi, E. Zilio, V. Ariu, S. Terziolo, M. Di Maio","doi":"10.48286/aro.2021.25","DOIUrl":"https://doi.org/10.48286/aro.2021.25","url":null,"abstract":"1 Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy 2 Department of Oncology, School of Medicine, University of Turin, Turin, Italy *Present address: Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy C. Zichi1,2, F. De Vita1,2, J. Paparo1,2, F. Salerno1,2, D. Marino1, E. Sperti1, G. Lacidogna1, F. Vignani1, R. Dionisio1, C. Baratelli1,2*, C. G. C. Turco1,2, D. Ballaminut1, A. Bellezza1, P. Chiotto1, G. Ciriolo1, R. Comite1, F. Codegone1, S. Florio1, L. Fusco1, L. Polimeno1, D. Pozzi1, E. Zilio1, V. Ariu1, S. Terzolo1, M. Di Maio1,2 ADOPTION OF PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE FOR OLDER PATIENTS RECEIVING ACTIVE ANTI-CANCER TREATMENT: IMPACT ON HEALTH-RELATED QUALITY OF LIFE Annals of Research in Oncology Vol. 1(4), 285-294, 2021","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116453479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Lasagna, S. Secondino, F. Agustoni, T. Monaco, I. Imarisio, A. Pagani, G. Rizzo, R. Tancredi, E. Pozzi, E. Ferraris, S. Chiellino, C. Gandini, A. Ferrari, S. Brugnatelli, P. Pedrazzoli
With the emergence of COVID-19, Oncologists have had to face up to the challenge of continuing active treatments without compromising patients and healthcare personnel’s safety. We introduced a double-step triage strategy (by phone and on site) for cancer patients in order to identify patients at risk of COVID-19 and to avoid their admission to our Oncology Unit. From February 24 th to April 7 th 2020
{"title":"THE RESILIENCE OF ONCOLOGISTS DURING THE EARLY TIME OF THE COVID-19 PANDEMIC","authors":"A. Lasagna, S. Secondino, F. Agustoni, T. Monaco, I. Imarisio, A. Pagani, G. Rizzo, R. Tancredi, E. Pozzi, E. Ferraris, S. Chiellino, C. Gandini, A. Ferrari, S. Brugnatelli, P. Pedrazzoli","doi":"10.48286/aro.2021.07","DOIUrl":"https://doi.org/10.48286/aro.2021.07","url":null,"abstract":"With the emergence of COVID-19, Oncologists have had to face up to the challenge of continuing active treatments without compromising patients and healthcare personnel’s safety. We introduced a double-step triage strategy (by phone and on site) for cancer patients in order to identify patients at risk of COVID-19 and to avoid their admission to our Oncology Unit. From February 24 th to April 7 th 2020","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128928850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Perrone, M. Tesei, E. De Crescenzo, C. Coadă, A. Bovicelli, S. Boussedra, S. Dondi, G. Giunchi, P. De Iaco
Epithelial Ovarian cancer is the most lethal and silent gynaecological tumor and relapses in about 75% of cases. Retrospective data supported the superiority of secondary cytoreduction surgery (SCS) plus chemotherapy versus chemotherapy alone; in order to best select patients for SCS literature established a clinical score based on ascites, performance status, and absence of residual disease to primary surgery. The present study analyzed the outcomes and pattern of relapse of a population with first relapse of ovarian cancer undergoing secondary surgery without residual tumor divided into two groups based on the type of treatment at the first diagnosis (primary debulking surgery [PDS] or neoadjuvant chemotherapy followed by interval debulking surgery [IDS]). This is an observational retrospective study carried out at the referred Centre of Oncologic Gynaecology of Bologna, Italy on patients who underwent SCS for ovarian cancer between January 2009 and December 2019 retrieved in an electronic data1 Division of Oncologic Gynaecology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy 2 Center for Applied Biomedical Research, Alma Mater Studiorum, University of Bologna, Bologna, Italy 3 University of Bologna, Bologna, Italy CORRESPONDING AUTHOR:
上皮性卵巢癌是最致命和沉默的妇科肿瘤，约75%的病例复发。回顾性数据支持二次细胞减少手术(SCS)加化疗优于单独化疗;为了最好地选择SCS患者，文献建立了一个基于腹水、功能状态和初级手术无残留疾病的临床评分。本研究分析了首次复发的无肿瘤残留的卵巢癌二次手术患者的预后和复发模式，根据首次诊断时的治疗方式分为两组(原发性减瘤手术[PDS]或新辅助化疗后间隔减瘤手术[IDS])。这是意大利博洛尼亚妇科肿瘤中心对2009年1月至2019年12月期间接受SCS治疗的卵巢癌患者进行的一项观察性回顾性研究，检索自电子数据1意大利博洛尼亚Azienda ospedaliero -博洛尼亚大学IRCCS肿瘤科2意大利博洛尼亚大学Alma Mater Studiorum应用生物医学研究中心3意大利博洛尼亚博洛尼亚大学通讯作者:
{"title":"PROGNOSTIC ROLE OF THE PRIMARY TREATMENT IN THE NATURAL HISTORY OF OVARIAN CANCER: A PILOT STUDY","authors":"A. Perrone, M. Tesei, E. De Crescenzo, C. Coadă, A. Bovicelli, S. Boussedra, S. Dondi, G. Giunchi, P. De Iaco","doi":"10.48286/aro.2021.13","DOIUrl":"https://doi.org/10.48286/aro.2021.13","url":null,"abstract":"Epithelial Ovarian cancer is the most lethal and silent gynaecological tumor and relapses in about 75% of cases. Retrospective data supported the superiority of secondary cytoreduction surgery (SCS) plus chemotherapy versus chemotherapy alone; in order to best select patients for SCS literature established a clinical score based on ascites, performance status, and absence of residual disease to primary surgery. The present study analyzed the outcomes and pattern of relapse of a population with first relapse of ovarian cancer undergoing secondary surgery without residual tumor divided into two groups based on the type of treatment at the first diagnosis (primary debulking surgery [PDS] or neoadjuvant chemotherapy followed by interval debulking surgery [IDS]). This is an observational retrospective study carried out at the referred Centre of Oncologic Gynaecology of Bologna, Italy on patients who underwent SCS for ovarian cancer between January 2009 and December 2019 retrieved in an electronic data1 Division of Oncologic Gynaecology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy 2 Center for Applied Biomedical Research, Alma Mater Studiorum, University of Bologna, Bologna, Italy 3 University of Bologna, Bologna, Italy CORRESPONDING AUTHOR:","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"85 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126235845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Cavanna, S. Casali, C. Citterio, G. Gianlupi, L. Pilla
The published studies of patients with COVID-19 and cancer are done on hospitalized patients, and data on early outpatient treatment of symptomatic COVID-19 cancer patients are unavailable in English literature. This study included a retrospective, single-center case series of 20 consecutive symptomatic non-hospitalized adults with laboratory confirmed or probable COVID-19 infection. The diagnosis of pneumonia was done with portable ultrasound (US). The treatment was based on hydroxychloroquine (HCQ) plus azithromycin (AZ), drugs allowed during the first wave. Oxygen was delivered when necessary, and enoxaparine was done in bedridden patients. The primary endpoint was clinical improvement or hospitalization considered as worsening of clinical conditions. The secondary endpoints were mortality at day 30 and at day 60. A finger oximeter was delivered to each patient and all patients were monitored by tele-medicine, the side effects of treatment were registered and reported. From March 13rd to May 26th, 2020, 180 patients with laboratory confirmed COVID-19 infection or with epidemiologically linked exposure to a person with laboratory confirmed infection were managed at home for COVID-19 in the district of Piacenza, Emilia Romagna Region. Among these 180 patients, 20 (11.11%) had cancer and form the basis of this report. There were 13 females (65%) and 7 males (35%), the majority of cancers were breast (40%) and gastrointestinal (30%). Seven patients (35%) were on active anticancer treatment when infected and all with metastatic disease, 13 patients (65%)
{"title":"COVID-19 outbreak in Italy. Report of 20 cancer patients with COVID-19 treated at home during the first wave","authors":"L. Cavanna, S. Casali, C. Citterio, G. Gianlupi, L. Pilla","doi":"10.48286/aro.2021.17","DOIUrl":"https://doi.org/10.48286/aro.2021.17","url":null,"abstract":"The published studies of patients with COVID-19 and cancer are done on hospitalized patients, and data on early outpatient treatment of symptomatic COVID-19 cancer patients are unavailable in English literature. This study included a retrospective, single-center case series of 20 consecutive symptomatic non-hospitalized adults with laboratory confirmed or probable COVID-19 infection. The diagnosis of pneumonia was done with portable ultrasound (US). The treatment was based on hydroxychloroquine (HCQ) plus azithromycin (AZ), drugs allowed during the first wave. Oxygen was delivered when necessary, and enoxaparine was done in bedridden patients. The primary endpoint was clinical improvement or hospitalization considered as worsening of clinical conditions. The secondary endpoints were mortality at day 30 and at day 60. A finger oximeter was delivered to each patient and all patients were monitored by tele-medicine, the side effects of treatment were registered and reported. From March 13rd to May 26th, 2020, 180 patients with laboratory confirmed COVID-19 infection or with epidemiologically linked exposure to a person with laboratory confirmed infection were managed at home for COVID-19 in the district of Piacenza, Emilia Romagna Region. Among these 180 patients, 20 (11.11%) had cancer and form the basis of this report. There were 13 females (65%) and 7 males (35%), the majority of cancers were breast (40%) and gastrointestinal (30%). Seven patients (35%) were on active anticancer treatment when infected and all with metastatic disease, 13 patients (65%)","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128457013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The SWI/SNF (Switch/Sucrose non-fermentable) complex is a key epigenetic regulator that is conserved across different species. While its functions as a gene expression regulator have been widely characterized, new evidences suggest that it can act as a fundamental modulator of metabolic pathways both in physiological and pathological processes. In this review, we summarized the most recent literature addressing molecular interactions involving members of the SWI/SNF complex and metabolic pathways. We focused on how genetic 1 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy 4 Scientific Direction, Centro di Riferimento Oncologico della Basilicata IRCCS-CROB, Rionero in Vulture, Potenza, Italy 5 David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
SWI/SNF(开关/蔗糖不可发酵)复合物是一个关键的表观遗传调控因子，在不同物种中是保守的。虽然其作为基因表达调节剂的功能已被广泛表征，但新的证据表明，它可以在生理和病理过程中作为代谢途径的基本调节剂。在这篇综述中，我们总结了涉及SWI/SNF复合体成员和代谢途径的分子相互作用的最新文献。我们关注的是遗传如何1基因组医学部，德克萨斯大学MD安德森癌症中心，休斯顿，德克萨斯州，美国2生殖泌尿医学肿瘤科，德克萨斯大学MD安德森癌症中心，休斯顿，德克萨斯州，美国3转化医学和外科，罗马，意大利4科学方向，巴西巴西肿瘤研究中心，ircs - crob，里奥内罗在Vulture, Potenza，5德克萨斯大学MD安德森癌症中心，生殖泌尿系统癌症应用研究David H. Koch中心，休斯顿，德克萨斯州，美国
{"title":"Targeting SWI/SNF metabolic vulnerabilities in cancer","authors":"M. Soeung, L. Perelli, A. Sgambato, G. Genovese","doi":"10.48286/aro.2021.31","DOIUrl":"https://doi.org/10.48286/aro.2021.31","url":null,"abstract":"The SWI/SNF (Switch/Sucrose non-fermentable) complex is a key epigenetic regulator that is conserved across different species. While its functions as a gene expression regulator have been widely characterized, new evidences suggest that it can act as a fundamental modulator of metabolic pathways both in physiological and pathological processes. In this review, we summarized the most recent literature addressing molecular interactions involving members of the SWI/SNF complex and metabolic pathways. We focused on how genetic 1 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy 4 Scientific Direction, Centro di Riferimento Oncologico della Basilicata IRCCS-CROB, Rionero in Vulture, Potenza, Italy 5 David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131983198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Covid-19 pandemic, which is still far from over, is continuing to take center stage in most debates on current cancer research and care. A year after Covid-19 outbreak and the first lockdown, it is clear that the disease had a heavy toll on cancer patients impacting on every stage from screening to diagnosis and treatment (1-3). With the availability of antiSARS-CoV2 vaccines, recent debates focused also on the vaccination strategies for cancer patients and for those eligible to access oncology clinical trials (4, 5). In our previous issue we discussed how the pandemic affected the number of new cancer diagnoses, showing a reduction compared to the same period in the preceding year (1, 6), and our authors presented some of the challenges faced from oncologists during the first wave of the pandemic (7, 8). In this issue of Annals of Research in Oncology, Lucia Fratino and Diego Serraino focus on some clear cut questions regarding SARS-CoV-2 infection, cancer, cancer therapies and immune suppression which demand attention and, possibly, guidelines, although recommendations for the management of cancer patients in the context of SARS-CoV-2 infection have been mostly produced outside the traditional “Evidence Based” benchmark because of the urgency (9). 1 Department of Medical Biotechnologies, University of Siena, Siena, Italy 2 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 3 Oncologia Medica, Clinical Cancer Center, AUSL-IRCCS, Reggio Emilia, Italy 4 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy A. Giordano 1,2, C. Pinto 3, F. Pentimalli 4 COVID-19 STILL ON CENTER STAGE IN ONCOLOGY DEBATES
Covid-19大流行仍远未结束，但在有关当前癌症研究和护理的大多数辩论中，它继续占据中心位置。在2019冠状病毒病爆发和第一次封锁一年后，很明显，这种疾病对癌症患者造成了沉重的代价，影响了从筛查到诊断和治疗的每个阶段(1-3)。随着抗sars - cov2疫苗的可用性，最近的争论也集中在癌症患者和有资格获得肿瘤临床试验的人的疫苗接种策略上(4,5)。在我们的上期杂志中，我们讨论了大流行如何影响新癌症诊断的数量，显示与去年同期相比有所减少(1,6)，我们的作者介绍了肿瘤学家在第一波大流行期间面临的一些挑战(7)。8)在这期《肿瘤研究年报》中，Lucia Fratino和Diego Serraino重点讨论了一些关于SARS-CoV-2感染、癌症、癌症治疗和免疫抑制的明确问题，这些问题需要关注，并可能需要制定指南，尽管由于紧迫性，在SARS-CoV-2感染背景下对癌症患者的管理建议大多是在传统的“基于证据”的基准之外提出的(9)。锡耶纳大学，锡耶纳，意大利2 Sbarro癌症研究和分子医学研究所，生物技术中心，天普大学，费城，宾夕法尼亚州3肿瘤学医学，临床癌症中心，AUSL-IRCCS，雷焦埃米利亚，意大利4细胞生物学和生物治疗单位，国立肿瘤研究所- irccs -基金会G. Pascale，意大利那不勒斯A. Giordano 1,2, C. Pinto 3, F. Pentimalli 4 COVID-19仍然在肿瘤争论的中心阶段
{"title":"COVID-19 still on center stage in Oncology debates","authors":"A. Giordano, C. Pinto, F. Pentimalli","doi":"10.48286/aro.2021.11","DOIUrl":"https://doi.org/10.48286/aro.2021.11","url":null,"abstract":"The Covid-19 pandemic, which is still far from over, is continuing to take center stage in most debates on current cancer research and care. A year after Covid-19 outbreak and the first lockdown, it is clear that the disease had a heavy toll on cancer patients impacting on every stage from screening to diagnosis and treatment (1-3). With the availability of antiSARS-CoV2 vaccines, recent debates focused also on the vaccination strategies for cancer patients and for those eligible to access oncology clinical trials (4, 5). In our previous issue we discussed how the pandemic affected the number of new cancer diagnoses, showing a reduction compared to the same period in the preceding year (1, 6), and our authors presented some of the challenges faced from oncologists during the first wave of the pandemic (7, 8). In this issue of Annals of Research in Oncology, Lucia Fratino and Diego Serraino focus on some clear cut questions regarding SARS-CoV-2 infection, cancer, cancer therapies and immune suppression which demand attention and, possibly, guidelines, although recommendations for the management of cancer patients in the context of SARS-CoV-2 infection have been mostly produced outside the traditional “Evidence Based” benchmark because of the urgency (9). 1 Department of Medical Biotechnologies, University of Siena, Siena, Italy 2 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 3 Oncologia Medica, Clinical Cancer Center, AUSL-IRCCS, Reggio Emilia, Italy 4 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy A. Giordano 1,2, C. Pinto 3, F. Pentimalli 4 COVID-19 STILL ON CENTER STAGE IN ONCOLOGY DEBATES","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125162543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Comandone, A. Boglione, T. Comandone, E. Giubellino, C. Oliva, P. Bergnolo
In metastatic soft tissue sarcomas (mSTS) second and further line of therapy are poorly defined. However many patients (pts), after first line therapy including Antracyclines progress in their disease and ask to be treated. Oral cyclophosphamide (CPM) was already used in breast cancer, prostate cancer and in one study in mSTS with contrasting results. Aim of our study was to define the feasibility, tolerability and activity of oral CPM as second and further line chemotherapy in mSTS patients: 45 pts (19 M; 26 F) median age 60 (32-81), with pretreated mSTS were included. Oral CPM was given daily at total dose of 50 mg/day without interruption excepted for toxicity or progressive disease. Results: leiomyosarcoma 12, liposarcoma 10, MPNST 5, synovialsarcoma 4, indifferentiated sarcoma 4, other rarer subtypes 10. Sites of the primary tumor were: extremities 21, retroperitoneum 19, trunk 5.41 pts were metastatic, 4 locally relapsed. All 45 pts were pretreated with chemotherapy (17 were in II line, 18 in III line, 8 in IV line, 2 in V line). Median PS (ECOG) was 2. Median duration of therapy was 4.4 months (from 1 to 38 months). The 6-month PFS rate was 46%. Treatment was well tolerated: neutropenia grade 2 in 1 case, fatigue grade 2 in 7 patients, nausea grade 1-2 in 22 cases. No grade 3-4 side effects were recorded.
{"title":"METRONOMIC CONTINUOUS ORAL CYCLOPHOSPHAMIDE (CPM) AS SECOND AND FURTHER LINE IN METASTATIC SOFT TISSUE SARCOMAS (STS) OF THE ADULT","authors":"A. Comandone, A. Boglione, T. Comandone, E. Giubellino, C. Oliva, P. Bergnolo","doi":"10.48286/aro.2021.16","DOIUrl":"https://doi.org/10.48286/aro.2021.16","url":null,"abstract":"In metastatic soft tissue sarcomas (mSTS) second and further line of therapy are poorly defined. However many patients (pts), after first line therapy including Antracyclines progress in their disease and ask to be treated. Oral cyclophosphamide (CPM) was already used in breast cancer, prostate cancer and in one study in mSTS with contrasting results. Aim of our study was to define the feasibility, tolerability and activity of oral CPM as second and further line chemotherapy in mSTS patients: 45 pts (19 M; 26 F) median age 60 (32-81), with pretreated mSTS were included. Oral CPM was given daily at total dose of 50 mg/day without interruption excepted for toxicity or progressive disease. Results: leiomyosarcoma 12, liposarcoma 10, MPNST 5, synovialsarcoma 4, indifferentiated sarcoma 4, other rarer subtypes 10. Sites of the primary tumor were: extremities 21, retroperitoneum 19, trunk 5.41 pts were metastatic, 4 locally relapsed. All 45 pts were pretreated with chemotherapy (17 were in II line, 18 in III line, 8 in IV line, 2 in V line). Median PS (ECOG) was 2. Median duration of therapy was 4.4 months (from 1 to 38 months). The 6-month PFS rate was 46%. Treatment was well tolerated: neutropenia grade 2 in 1 case, fatigue grade 2 in 7 patients, nausea grade 1-2 in 22 cases. No grade 3-4 side effects were recorded.","PeriodicalId":148778,"journal":{"name":"Annals of Research in Oncology","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116852993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：